Biomea Fusion Inc (BMEA)

$1.58 +0.01 (0.64%)
Market Cap 113.51M
Revenue (ttm) 0.00
Net Income (ttm) -61.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 585,100
Avg Vol 1,617,548
Day's Range N/A - N/A
Shares Out 72.30M
Stochastic %K 67%
Beta -0.32
Analysts Strong Sell
Price Target $7.57

Company Profile

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, whic...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 980 9099
Address:
1599 Industrial Road, San Carlos, United States
ham_and_egger
ham_and_egger May. 13 at 11:33 AM
$BMEA holding and adding for gold.
0 · Reply
Creisi
Creisi May. 13 at 10:05 AM
$BMEA If you look at existing diabetic medications, all of them plateau and then start losing clinical effect; eventually moving the T2D patient to insulin. Icovamenib's near zero ADA (anti-drug antibody) effect is vastly superior and will NOT see a degradation in efficacy or safety long term. In fact, the longer a person is on it, the more efficacious the drug will become. This is why we should see even better results the longer a clinical trial goes.
0 · Reply
Creisi
Creisi May. 13 at 9:43 AM
$BMEA Speaking of ADA for SLK in HS makes be want to elaborate on a major advantage of all Biomea Fusion's drugs. Icovamenib exhibits far lower Anti-Drug Antibody (ADA) rates presenting 0% or near-zero immunogenicity. This is verified through ridiculously low ADA rates in the blood. It is the covalent nature of these drugs which inhibit AntiDrug Antibodies from developing in patients over long term usage. This is why their effectiveness will have no efficacy and safety plateaus and will almost always become even more effective the longer a person is exposed to the drug. From a scientific perspective it makes BMEA's drugs far more advanced than competitors. This advancement will show itself over long term trials as being even more effective than at shorter primary endpoints making long term efficacy and safety far easier to predict.
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 13 at 1:22 AM
$BMEA
0 · Reply
BiomeaIR
BiomeaIR May. 13 at 12:05 AM
$BMEA Biomea Fusion management will be presenting at two upcoming investor conferences. Join us for our fireside chats and one-on-one meetings in New York, NY: • H.C. Wainwright 4th Annual BioConnect Investor Conference | May 19, 2026 | 3:00–3:30 PM ET • Jefferies Global Healthcare Conference | June 4, 2026 | 8:10–8:40 AM ET Audio webcasts as well as replays will be available. Visit our Investors & Media page for details. For 1:1 meeting requests, please reach out to Meichiel Weiss, Sr. Director of Investor Relations & Corporate Development, at [email protected]. Read the full press release: https://bit.ly/biomea-press-release-051226-stocktwits
0 · Reply
TradesTyrone
TradesTyrone May. 12 at 5:54 PM
$BMEA $MLTX Grabbed a few in the 18s on MLTX. Don't judge me.
1 · Reply
Creisi
Creisi May. 12 at 4:19 PM
$BMEA The catalyst which will drive share price with sustained results in the short term is BMF-650, the only 24/7 covalent GLP-1 in development. These results will be posted at any moment through a press release or a corporate conference call and given their distinct small molecule, covalent binding nature; they're a lock to be best in class. As for the 1st quarter results, they came in better than even the Bulls thought they would with a 60% cut in R&D to only $9.1 million; erasing the crazy talk of bankruptcy this summer by the nut job short sellers. The company is clearly funded into Q1 of 2027 just as Mick Hitchcock said back in December 2025.
1 · Reply
Creisi
Creisi May. 12 at 3:49 PM
$BMEA
0 · Reply
BioFlare
BioFlare May. 12 at 3:43 PM
$BMEA GM. After reading the financial results and corporate highlights, I see way more positives than negatives. Chronic tox for icovamenib is done, which supports longer clinical dosing. T1D data still looks good. The T2D trials are now moving, with data expected in Q4 2026. BMF-650 obesity data is still expected this quarter. They also cut spending a lot while keeping the main programs on track. Yes, cash runway into Q1 2027 is still a thing to pay attention to, but overall, the positives way outweigh the negatives.
0 · Reply
focafoca99
focafoca99 May. 12 at 4:00 AM
$BMEA released its March‑31, 2026 quarter results via a press release.
0 · Reply
Latest News on BMEA
Biomea Fusion to Participate at Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 16 hours ago

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion reports Q1 EPS (17c), consensus (19c)

2026-05-11T23:09:08.000Z - 1 day ago

Biomea Fusion reports Q1 EPS (17c), consensus (19c)

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

May 11, 2026, 4:54 PM EDT - 1 day ago

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion options imply 18.9% move in share price post-earnings

2026-05-08T19:05:38.000Z - 4 days ago

Biomea Fusion options imply 18.9% move in share price post-earnings

Biomea Fusion options imply 23.1% move in share price post-earnings

2026-05-07T02:00:17.000Z - 6 days ago

Biomea Fusion options imply 23.1% move in share price post-earnings

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

May 5, 2026, 5:50 PM EDT - 7 days ago

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

Biomea Fusion Transcript: Status update

May 5, 2026, 2:30 PM EDT - 7 days ago

Biomea Fusion Transcript: Status update

Biomea Fusion initiated with an Outperform at Citizens

2026-05-05T08:25:12.000Z - 8 days ago

Biomea Fusion initiated with an Outperform at Citizens

Biomea Fusion options imply 22.0% move in share price post-earnings

2026-05-04T19:15:13.000Z - 8 days ago

Biomea Fusion options imply 22.0% move in share price post-earnings

Biomea Fusion Transcript: Study result

Apr 28, 2026, 8:30 AM EDT - 15 days ago

Biomea Fusion Transcript: Study result

Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial

2026-04-27T21:40:11.000Z - 15 days ago

Biomea Fusion announces positive 52-week results from phase 2 COVALENT-112 trial

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Apr 27, 2026, 5:37 PM EDT - 15 days ago

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials

2026-03-31T11:24:55.000Z - 6 weeks ago

Biomea Fusion doses first patient in COVALENT-211, COVALENT-212 trials

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Mar 31, 2026, 7:00 AM EDT - 6 weeks ago

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 3:00 PM EDT - 6 weeks ago

Biomea Fusion Transcript: Fireside chat

Biomea Fusion Transcript: Fireside chat

Mar 30, 2026, 1:00 PM EDT - 6 weeks ago

Biomea Fusion Transcript: Fireside chat

Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’

2026-03-27T10:32:33.000Z - 6 weeks ago

Citi ups Biomea Fusion target, adds ‘upside 90-day catalyst watch’

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Mar 24, 2026, 4:05 PM EDT - 7 weeks ago

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes

2026-03-15T14:50:06.000Z - 2 months ago

Biomea Fusion presents Phase II Covalent-111 data in Type 2 Diabetes

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Mar 14, 2026, 4:30 AM EDT - 2 months ago

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Biomea Fusion Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 2:50 PM EDT - 2 months ago

Biomea Fusion Transcript: The Citizens Life Sciences Conference 2026

Biomea Fusion management to meet virtually with Craig-Hallum

2026-03-04T15:46:54.000Z - 2 months ago

Biomea Fusion management to meet virtually with Craig-Hallum

Biomea Fusion Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 10:00 AM EST - 2 months ago

Biomea Fusion Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Biomea Fusion Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 4 months ago

Biomea Fusion Transcript: 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion initiated with a Buy at Rodman & Renshaw

2026-01-13T20:20:23.000Z - 4 months ago

Biomea Fusion initiated with a Buy at Rodman & Renshaw

Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestones

2026-01-12T13:40:46.000Z - 4 months ago

Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestones

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Jan 12, 2026, 8:00 AM EST - 4 months ago

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 7:00 AM EST - 5 months ago

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion announces KOL presentation

2025-12-10T01:05:10.000Z - 5 months ago

Biomea Fusion announces KOL presentation

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Dec 9, 2025, 6:35 PM EST - 5 months ago

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Biomea Fusion presents COVALENT-111 study results at WCIRDC

2025-12-05T12:10:07.000Z - 5 months ago

Biomea Fusion presents COVALENT-111 study results at WCIRDC

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 5, 2025, 7:00 AM EST - 5 months ago

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 7:30 AM EST - 5 months ago

Biomea Fusion Transcript: Evercore ISI 8th Annual HealthCONx Conference

Biomea Fusion Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 8:00 AM EST - 5 months ago

Biomea Fusion Transcript: Piper Sandler 37th Annual Healthcare Conference

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 1, 2025, 4:10 PM EST - 5 months ago

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Dec 1, 2025, 4:05 PM EST - 5 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 11:30 AM EST - 6 months ago

Biomea Fusion Transcript: Jefferies London Healthcare Conference 2025

Biomea Fusion downgraded to Underweight from Neutral at JPMorgan

2025-11-15T15:15:11.000Z - 6 months ago

Biomea Fusion downgraded to Underweight from Neutral at JPMorgan

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Nov 10, 2025, 7:00 AM EST - 6 months ago

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Biomea Fusion price target lowered to $6 from $7 at Citi

2025-11-10T11:35:48.000Z - 6 months ago

Biomea Fusion price target lowered to $6 from $7 at Citi

Biomea Fusion announces presentation of two posters for BMF-650, icovamenib

2025-11-05T12:41:37.000Z - 6 months ago

Biomea Fusion announces presentation of two posters for BMF-650, icovamenib

Biomea Fusion price target lowered to $12 from $16 at D. Boral Capital

2025-11-05T12:20:51.000Z - 6 months ago

Biomea Fusion price target lowered to $12 from $16 at D. Boral Capital

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Nov 5, 2025, 7:00 AM EST - 6 months ago

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Biomea Fusion reports Q3 EPS (27c), consensus (29c)

2025-11-04T22:01:16.000Z - 6 months ago

Biomea Fusion reports Q3 EPS (27c), consensus (29c)

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 4, 2025, 4:05 PM EST - 6 months ago

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Biomea Fusion announces first patient dosed in Phase I trial of BMF-650

2025-10-27T12:15:32.000Z - 7 months ago

Biomea Fusion announces first patient dosed in Phase I trial of BMF-650

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Biomea Fusion Transcript: Citi's 2025 SMID Cap Biopharma Call Series

Oct 23, 2025, 11:00 AM EDT - 7 months ago

Biomea Fusion Transcript: Citi's 2025 SMID Cap Biopharma Call Series

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Oct 21, 2025, 7:05 PM EDT - 7 months ago

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Biomea Fusion Transcript: Study Result

Oct 7, 2025, 8:30 AM EDT - 7 months ago

Biomea Fusion Transcript: Study Result

Biomea Fusion Announces Pricing of Public Offering of Securities

Oct 7, 2025, 8:00 AM EDT - 7 months ago

Biomea Fusion Announces Pricing of Public Offering of Securities

Biomea Fusion Announces Proposed Public Offering of Securities

Oct 6, 2025, 4:18 PM EDT - 7 months ago

Biomea Fusion Announces Proposed Public Offering of Securities

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Oct 6, 2025, 4:03 PM EDT - 7 months ago

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Sep 16, 2025, 7:00 AM EDT - 8 months ago

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 23, 2025, 7:00 AM EDT - 11 months ago

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 18, 2025, 7:00 AM EDT - 11 months ago

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Jun 18, 2025, 6:28 AM EDT - 11 months ago

Biomea Fusion Shares Fall After Pricing Underwritten Public Offering

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

Jun 17, 2025, 7:28 PM EDT - 11 months ago

Stocks to Watch: Biomea Fusion, Bitdeer Technologies

BTDR

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Jun 13, 2025, 6:45 AM EDT - 11 months ago

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

May 14, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

May 5, 2025, 4:05 PM EDT - 1 year ago

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 4:01 PM EDT - 1 year ago

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 31, 2025, 4:10 PM EDT - 1 year ago

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Biomea Fusion Announces Leadership Transition

Mar 25, 2025, 7:00 PM EDT - 1 year ago

Biomea Fusion Announces Leadership Transition

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

Biomea Fusion Transcript: Status Update

Mar 19, 2025, 1:00 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update

Biomea Fusion Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Biomea Fusion Transcript: Barclays 27th Annual Global Healthcare Conference

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Feb 27, 2025, 8:00 AM EST - 1 year ago

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

Biomea Fusion Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 10:40 AM EST - 1 year ago

Biomea Fusion Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Biomea Fusion Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Dec 17, 2024, 8:10 AM EST - 1 year ago

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion Transcript: Study Result

Dec 17, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion Transcript: Study Result

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Dec 16, 2024, 6:15 PM EST - 1 year ago

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 12, 2024, 5:02 PM EST - 1 year ago

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Biomea Fusion Transcript: Study Update

Dec 9, 2024, 4:30 PM EST - 1 year ago

Biomea Fusion Transcript: Study Update

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Dec 9, 2024, 4:01 PM EST - 1 year ago

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Dec 6, 2024, 8:00 AM EST - 1 year ago

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

Biomea Fusion Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 5, 2024, 7:55 AM EST - 1 year ago

Biomea Fusion Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Biomea Fusion Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 10:00 AM EST - 1 year ago

Biomea Fusion Transcript: Piper Sandler 36th Annual Healthcare Conference

Biomea Fusion Transcript: Status Update

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Biomea Fusion Transcript: Status Update

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Oct 30, 2024, 4:00 PM EDT - 1 year ago

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

Oct 29, 2024, 4:46 PM EDT - 1 year ago

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

ham_and_egger
ham_and_egger May. 13 at 11:33 AM
$BMEA holding and adding for gold.
0 · Reply
Creisi
Creisi May. 13 at 10:05 AM
$BMEA If you look at existing diabetic medications, all of them plateau and then start losing clinical effect; eventually moving the T2D patient to insulin. Icovamenib's near zero ADA (anti-drug antibody) effect is vastly superior and will NOT see a degradation in efficacy or safety long term. In fact, the longer a person is on it, the more efficacious the drug will become. This is why we should see even better results the longer a clinical trial goes.
0 · Reply
Creisi
Creisi May. 13 at 9:43 AM
$BMEA Speaking of ADA for SLK in HS makes be want to elaborate on a major advantage of all Biomea Fusion's drugs. Icovamenib exhibits far lower Anti-Drug Antibody (ADA) rates presenting 0% or near-zero immunogenicity. This is verified through ridiculously low ADA rates in the blood. It is the covalent nature of these drugs which inhibit AntiDrug Antibodies from developing in patients over long term usage. This is why their effectiveness will have no efficacy and safety plateaus and will almost always become even more effective the longer a person is exposed to the drug. From a scientific perspective it makes BMEA's drugs far more advanced than competitors. This advancement will show itself over long term trials as being even more effective than at shorter primary endpoints making long term efficacy and safety far easier to predict.
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 13 at 1:22 AM
$BMEA
0 · Reply
BiomeaIR
BiomeaIR May. 13 at 12:05 AM
$BMEA Biomea Fusion management will be presenting at two upcoming investor conferences. Join us for our fireside chats and one-on-one meetings in New York, NY: • H.C. Wainwright 4th Annual BioConnect Investor Conference | May 19, 2026 | 3:00–3:30 PM ET • Jefferies Global Healthcare Conference | June 4, 2026 | 8:10–8:40 AM ET Audio webcasts as well as replays will be available. Visit our Investors & Media page for details. For 1:1 meeting requests, please reach out to Meichiel Weiss, Sr. Director of Investor Relations & Corporate Development, at [email protected]. Read the full press release: https://bit.ly/biomea-press-release-051226-stocktwits
0 · Reply
TradesTyrone
TradesTyrone May. 12 at 5:54 PM
$BMEA $MLTX Grabbed a few in the 18s on MLTX. Don't judge me.
1 · Reply
Creisi
Creisi May. 12 at 4:19 PM
$BMEA The catalyst which will drive share price with sustained results in the short term is BMF-650, the only 24/7 covalent GLP-1 in development. These results will be posted at any moment through a press release or a corporate conference call and given their distinct small molecule, covalent binding nature; they're a lock to be best in class. As for the 1st quarter results, they came in better than even the Bulls thought they would with a 60% cut in R&D to only $9.1 million; erasing the crazy talk of bankruptcy this summer by the nut job short sellers. The company is clearly funded into Q1 of 2027 just as Mick Hitchcock said back in December 2025.
1 · Reply
Creisi
Creisi May. 12 at 3:49 PM
$BMEA
0 · Reply
BioFlare
BioFlare May. 12 at 3:43 PM
$BMEA GM. After reading the financial results and corporate highlights, I see way more positives than negatives. Chronic tox for icovamenib is done, which supports longer clinical dosing. T1D data still looks good. The T2D trials are now moving, with data expected in Q4 2026. BMF-650 obesity data is still expected this quarter. They also cut spending a lot while keeping the main programs on track. Yes, cash runway into Q1 2027 is still a thing to pay attention to, but overall, the positives way outweigh the negatives.
0 · Reply
focafoca99
focafoca99 May. 12 at 4:00 AM
$BMEA released its March‑31, 2026 quarter results via a press release.
0 · Reply
BiomeaIR
BiomeaIR May. 12 at 12:22 AM
$BMEA Q1 2026 financial results and pipeline updates across our diabetes and obesity programs: • Icovamenib chronic tox studies successfully completed, providing non-clinical support for advancing to chronic clinical dosing • COVALENT-112 (icovamenib | T1D): 52-week follow-up data reported, supporting proposed MOA • COVALENT-211 & COVALENT-212 (icovamenib | T2D): First patients dosed in Phase II clinical trials; topline 26-week data expected Q4 2026 • GLP-131 (BMF-650 | obesity): Phase I clinical trial on track; initial 28-day weight reduction data expected Q2 2026 Read the full press release: https://bit.ly/biomea-press-release-051126-stocktwits
0 · Reply
Arxidia
Arxidia May. 11 at 9:33 PM
$BMEA ok so as far as I can tell, today’s highlights from the earnings report: a) tox studies have proven that good old icovamenib is safe for long-term use thus putting to bed any lingering shadows from the 2024 fda hold b) confirmation that t1d data is solid …“topline data supporting proposed mechanism of action" … and that the proof will be presented in the ADA posters c) re-confirmation that the bmf650 data is on time for this quarter So science execution wise - not bad at all.
1 · Reply
Mr_GA
Mr_GA May. 11 at 9:06 PM
$BMEA Link: https://finance.yahoo.com/sectors/healthcare/articles/biomea-fusion-reports-first-quarter-205400887.html
0 · Reply
Rifraf
Rifraf May. 11 at 9:02 PM
$BMEA
0 · Reply
hashbridges
hashbridges May. 11 at 4:01 PM
$BMEA cool trick to take out that much price on that little volume.
0 · Reply
TradesTyrone
TradesTyrone May. 11 at 2:17 PM
$BMEA $MLTX I’ll probably kick myself later for this but I’m taking some gains here in both of these. Reducing risk and needed to raise some more cash. Letting a good chunk ride though.
5 · Reply
septrading
septrading May. 11 at 2:12 PM
$MLTX $BMEA six-figure gain days are always wonderful. Science makes millionaires.
1 · Reply
dmcintyre92
dmcintyre92 May. 11 at 1:51 PM
$BMEA looking good this morning
0 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 11 at 1:29 PM
$BMEA earnings now on 18th... My guess for possible setup: • aligning earnings with fresh ADA/icovamenib updates • strategic partnership discussions • financing from a stronger position after data • tightening disclosures ahead of major announcements At this valuation, even ONE strong partnership, licensing deal, or clean efficacy update will again completely rerate the stock. Market cap still pricing in a good amount of hesitation towards the science... But the science narrative keeps getting stronger in leaps and bounds 🧬🔬📈 Exciting times ahead dear Ladies and Gentlemen 💲💲💲
0 · Reply
Mr_GA
Mr_GA May. 11 at 1:21 AM
$BMEA OFF TOPIC; Did anyone here pick up any ENGN after the big drop?
1 · Reply
RKLBupupup
RKLBupupup May. 10 at 8:14 PM
$BMEA Showing lot of weakness.Sitting on hands and waiting on news.
0 · Reply
Rob88ynn
Rob88ynn May. 10 at 2:44 AM
$BMEA
0 · Reply